iHuman Inc. (IH)

NYQ – Цена в реальном времени. Валюта: USD

1.40

+0.02 (1.45%)

При закрытии: Jun 26, 2026, 1:25 PM EDT

1.40

0.00 (0.00%)

После закрытия: Jun 26, 2026, 5:05 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

iHuman Inc. (IH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

iHuman Inc. (IH)

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Видео

No Data

Пресс-релизы

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

Search stocks

iHuman Inc. (IH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

iHuman Inc. (IH)

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Видео

No Data

Пресс-релизы

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results